QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:NLTX

Neoleukin Therapeutics Stock Forecast, Price & News

$13.62
+0.28 (+2.10 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.90
Now: $13.62
$13.66
50-Day Range
$10.77
MA: $13.33
$15.78
52-Week Range
$5.81
Now: $13.62
$18.13
Volume178,084 shs
Average Volume358,943 shs
Market Capitalization$571.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

607th out of 1,922 stocks

Pharmaceutical Preparations Industry

308th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NLTX
CUSIPN/A
CIKN/A
Phone206-732-2133
Employees65
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$2.91 per share

Profitability

Net Income$-69,440,000.00

Miscellaneous

Market Cap$571.15 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$13.62
+0.28 (+2.10 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NLTX News and Ratings via Email

Sign-up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions

How has Neoleukin Therapeutics' stock price been impacted by COVID-19?

Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NLTX shares have increased by 71.1% and is now trading at $13.62.
View which stocks have been most impacted by COVID-19
.

Is Neoleukin Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neoleukin Therapeutics stock.
View analyst ratings for Neoleukin Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Neoleukin Therapeutics?

Wall Street analysts have given Neoleukin Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neoleukin Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Neoleukin Therapeutics' next earnings date?

Neoleukin Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Neoleukin Therapeutics
.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its quarterly earnings data on Monday, November, 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03.
View Neoleukin Therapeutics' earnings history
.

What price target have analysts set for NLTX?

8 analysts have issued twelve-month target prices for Neoleukin Therapeutics' shares. Their forecasts range from $18.00 to $30.00. On average, they anticipate Neoleukin Therapeutics' share price to reach $21.75 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts' price targets for Neoleukin Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Neoleukin Therapeutics' key competitors?

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), Raytheon Technologies (RTX), Honeywell International (HON), The Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and The Home Depot (HD).

Who are Neoleukin Therapeutics' key executives?

Neoleukin Therapeutics' management team includes the following people:
  • Dr. Jonathan G. Drachman, CEO, Pres & Director (Age 58, Pay $585.81k)
  • Mr. Kamran Alam, Sr. Strategic Advisor (Age 46, Pay $1.2M)
  • Dr. David Baker, Co-founder & Member of Scientific Advisory Board
  • Mr. Robert Ho, CFO & Sec. (Age 44)
  • Ms. Holly K. Vance, Gen. Counsel
  • Dr. Carl Walkey, VP of Corp. Devel.
  • Ms. Samantha Willing, VP of People
  • Dr. Daniel-Adriano Silva Manzano, VP & Head of Research
  • Mr. Umut Ulge, VP of Clinical Devel.

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Clarius Group LLC (0.06%) and Janney Montgomery Scott LLC (0.02%). Company insiders that own Neoleukin Therapeutics stock include Bros Advisors Lp Baker, Jonathan G Drachman and Redmile Group, Llc.
View institutional ownership trends for Neoleukin Therapeutics
.

Which institutional investors are buying Neoleukin Therapeutics stock?

NLTX stock was acquired by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC, and Clarius Group LLC. Company insiders that have bought Neoleukin Therapeutics stock in the last two years include Bros Advisors Lp Baker, Jonathan G Drachman, and Redmile Group, Llc.
View insider buying and selling activity for Neoleukin Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $13.62.

How big of a company is Neoleukin Therapeutics?

Neoleukin Therapeutics has a market capitalization of $571.15 million and generates $25 million in revenue each year. The company earns $-69,440,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Neoleukin Therapeutics employs 65 workers across the globe.

What is Neoleukin Therapeutics' official website?

The official website for Neoleukin Therapeutics is www.neoleukin.com.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The company can be reached via phone at 206-732-2133 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.